| March 1, 2027 |
SXTP |
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis |
Trial Milestone |
Phase 2 |
| March 1, 2027 |
APLM |
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS |
Trial Milestone |
Phase 1 |
| March 6, 2027 |
MRNA |
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. |
Trial Milestone |
Phase 2 |
| March 11, 2027 |
BMY |
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer |
Trial Milestone |
Phase 3 |
| March 12, 2027 |
TVTX |
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases |
Trial Milestone |
Phase 2 |
| March 13, 2027 |
RYTM |
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) |
Trial Milestone |
Phase 3 |
| March 15, 2027 |
LLY |
A Study of LY4515100 in Healthy Participants |
Trial Milestone |
Phase 1 |
| March 15, 2027 |
ABBV |
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder |
Trial Milestone |
Phase 2 |
| March 15, 2027 |
ABBV |
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) |
Trial Milestone |
Phase 2 |
| March 15, 2027 |
ABBV |
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. |
Trial Milestone |
Phase 3 |
| March 15, 2027 |
ARGX |
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis |
Trial Milestone |
Phase 2/Phase 3 |
| March 15, 2027 |
ARGX |
A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| March 15, 2027 |
ONC |
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2027 |
IONS |
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) |
Trial Milestone |
Phase 3 |
| March 15, 2027 |
VNDA |
Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2027 |
BMRN |
A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment |
Trial Milestone |
Phase 2 |
| March 15, 2027 |
IBRX |
A Study to Examine Anktiva for the Treatment of COVID-19. |
Trial Milestone |
Phase 2 |
| March 15, 2027 |
NUVB |
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2027 |
FDMT |
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2027 |
OCUL |
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy |
Trial Milestone |
Phase 3 |
| March 15, 2027 |
MDGL |
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) |
Trial Milestone |
Phase 3 |
| March 15, 2027 |
OCGN |
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2027 |
CLDX |
A Study of CDX-622 in Participants With Mild to Moderate Asthma |
Trial Milestone |
Phase 1 |
| March 15, 2027 |
PCVX |
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination |
Trial Milestone |
Phase 3 |
| March 15, 2027 |
PCVX |
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age |
Trial Milestone |
Phase 3 |
| March 15, 2027 |
URGN |
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer |
Trial Milestone |
Phase 3 |
| March 15, 2027 |
TVTX |
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis |
Trial Milestone |
Phase 4 |
| March 15, 2027 |
DNLI |
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) |
Trial Milestone |
Phase 2 |
| March 15, 2027 |
COGT |
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2027 |
EWTX |
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy |
Trial Milestone |
Phase 2 |
| March 15, 2027 |
STOK |
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome |
Trial Milestone |
Phase 3 |
| March 15, 2027 |
TYRA |
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations |
Trial Milestone |
Phase 1 |
| March 15, 2027 |
AURA |
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer |
Trial Milestone |
Phase 1 |
| March 15, 2027 |
MNKD |
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes |
Trial Milestone |
Phase 2 |
| March 16, 2027 |
TAK |
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura |
Trial Milestone |
Phase 3 |
| March 22, 2027 |
MRK |
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) |
Trial Milestone |
Phase 2 |
| March 22, 2027 |
REGN |
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) |
Trial Milestone |
Phase 3 |
| March 22, 2027 |
INSM |
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants |
Trial Milestone |
Phase 1 |
| March 23, 2027 |
NVS |
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults |
Trial Milestone |
Phase 2 |
| March 23, 2027 |
AMGN |
Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose |
Trial Milestone |
Phase 1 |
| March 27, 2027 |
INCY |
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation |
Trial Milestone |
Phase 1 |
| March 29, 2027 |
BMY |
A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses |
Trial Milestone |
Phase 1 |
| March 30, 2027 |
PFE |
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma |
Trial Milestone |
Phase 1 |
| March 30, 2027 |
INCY |
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Impaired Renal Function and Participants on Hemodialysis |
Trial Milestone |
Phase 1 |
| March 31, 2027 |
JNJ |
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer |
Trial Milestone |
Phase 1 |
| March 31, 2027 |
INCY |
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment |
Trial Milestone |
Phase 1 |
| March 31, 2027 |
ONC |
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| March 31, 2027 |
AAPG |
A Study of Olverembatinib in SDH-deficient GIST. |
Trial Milestone |
Phase 3 |
| March 31, 2027 |
RVMD |
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors |
Trial Milestone |
Phase 1 |
| March 31, 2027 |
VTRS |
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus |
Trial Milestone |
Phase 3 |
| March 31, 2027 |
CGON |
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC |
Trial Milestone |
Phase 2 |
| March 31, 2027 |
TNGX |
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss |
Trial Milestone |
Phase 1/Phase 2 |
| March 31, 2027 |
HURA |
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma |
Trial Milestone |
Phase 2/Phase 3 |